Insilico Medicine's pan-TEAD inhibitor ISM6331 receives FDA IND clearance for mesothelioma treatment
Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced ISM6331, potential best-in-class pan-TEAD inhibitor, has received the U.S. Food and Drug Administration (FDA) …